UMIN-CTR Clinical Trial

Public title

Efficacy and safety of new drugs for induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed symptomatic multiple myeloma: a phase 2 study

Acronym

JSCT-MM16

Scientific Title

Efficacy and safety of new drugs for induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed symptomatic multiple myeloma: a phase 2 study

Scientific Title:Acronym

JSCT-MM16

Region

Japan

Condition

Multiple myeloma

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO

Narrative objectives1

The purpose of this study is to investigate efficacy and safety of new drugs in each phase of treatment in patients with newly diagnosed symptomatic multiple myeloma, and to investigate efficacy of detection of minimal residual disease (MRD).

Induction therapy: bortezomib, lenalidomide, and dexamethasone (VRD).
Conditioning regimen in autologous stem cell transplantation: bortezomib and high-dose melphalan.
Consolidation therapy: carfilzomib, lenalidomide, and dexamethasone (KRD).
Maintenance therapy: lenalidomide (until-PD).

Basic objectives2

Safety,Efficacy

Basic objectives -Others

Trial characteristics_1

Trial characteristics_2

Developmental phase

Primary outcomes

Complete response (CR) rates after consolidation therapy.

Key secondary outcomes

1. CR + stringent CR (sCR) rates after induction therapy.
2. CR + sCR rates after autologous stem cell transplantation.
3. sCR rates after consolidation therapy.
4. CR + sCR rates after maintenance therapy.
5. 3-years progression free survival (PFS)
6. 3-years overall survival (OS)
7. 3-years Time to Treatment Failure (TTF)
8. Incidence of adverse events.
9. Molecular complete response (mCR) rates after autologous stem cell transplantation, consolidation and maintenance therapy.
10. Detection of minimal residual disease (MRD) in autologous grafts

Study type

Interventional

Basic design

Single arm

Randomization

Non-randomized

Randomization unit

Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

Dynamic allocation

Institution consideration

Blocking

Concealment

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Induction therapy (4 courses, every 3 weeks)
scBor 1.3mg/m2 day1,4,8,11 + Len 25mg/body day1-14 + Dex 40mg/body day1,4,8,11

PBSC harvest
scBor 1.3mg/m2 day1,4,8,11 + CY 1.5g/m2 day8,9 + G-CSF

High dose chemotherapy and PBSCT
scBor 1.3mg/m2 day-4,-1,3,6 + HD-Mel 100mg/m2 day-3,-2 PBSCT day0

Consolidation therapy (4 courses, every 4 weeks)
Cfz 20/27mg/m2 day1,2,8,9,15,16 + Len 25mg/body day1-21 + Dex 40mg/body day1,8,15

Maintenance therapy (every 4 weeks until PD)
Len 10mg/day day1-21 until-PD

Interventions/Control_2

Interventions/Control_3

Interventions/Control_4

Interventions/Control_5

Interventions/Control_6

Interventions/Control_7

Interventions/Control_8

Interventions/Control_9

Interventions/Control_10

Age-lower limit

20

years-old

<=

Age-upper limit

65

years-old

>=

Gender

Male and Female

Key inclusion criteria

1. Age from 20 to 65 years old.
2. Symptomatic multiple myeloma diagnosed by the criteria of International Myeloma Working Group (IMWG).
3. Measureable M protein in serum or urine or abnormal serum kappa/lambda ratio by the serum free light chain measurement.
4. Good performance status (0-2). (Patients with poor performance status by the osteolytic lesions can be included.)
5. Main Organ function is maintained
6. Those who are evaluated to be able to survive more than 3 months.
7. For female patients, postmenopausal (patients older than one year from the last menstrual period), or the proper way or surgical contraception (birth control pills, contraceptives, etc.) has the intention of contraception during the study according to the proposal of RevMate. For male patients, to agree the appropriate method of contraception during the study according to the proposal of RevMate.
8. In patients receiving the notice, fully briefed for the consent document and other documents given explanation about the contents of the study physician or study investigator, agreed in writing to voluntarily participate in the study by having been obtained.

Key exclusion criteria

1. Non-secretory MM, plasma cell leukemia, POEMS syndrome, and Waldenstrom Macroglobulinemia.
2. Patients with amyloidosis.
3. Patients who have been undergoing surgery or radiation treatment within 14 days before participating the study.
4. Patients who received prednisolone more than 30mg/day within 14 days before participation.
5. Involvement of central nervus system with myeloma cells
6. Patients HIV-positive, HBs antigen positive, and HCV antibody positive (except HCV-PCR negative).
7. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection.
8. Patients with a history of active malignancy during the past 5 years.
9. Patients with psychiatric disorders such as schizophrenia etc.
10. Pregnant women, pre-menopausal women, and lactating women.
11. History of hypersensitivity to mannitol or boron.
12. Patient was suspected pneumonia (Interstitial pneumonia). Consult a respiratory specialist if necessary
13. Those who are considered as inappropriate to register by attending physicians.

Target sample size

133

Name of lead principal investigator

1st name
Middle name
Last name	Toshihiro Miyamoto

Organization

Kyushu University Graduate School of Medical Science

Division name

Department of Medicine and Biosystemic Science

Zip code

Address

Fukuoka, Japan

TEL

092-

Email

jsct-office@umin.ac.jp

Name of contact person

1st name
Middle name
Last name	Toshihiro Miyamoto

Organization

JSCT

Division name

MM16 DC

Zip code

Address

104-0031

TEL

03-6225-2025

Homepage URL

Email

jsct-office@umin.ac.jp

Institute

JSCT

Institute

Department

Personal name

Organization

CELGENE K.K.
ONO PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Co-sponsor

Name of secondary funder(s)

Organization

Address

Tel

Email

Secondary IDs

NO

Study ID_1

Org. issuing International ID_1

Study ID_2

Org. issuing International ID_2

IND to MHLW

Institutions

Date of disclosure of the study information

2017

Year

02

Month

01

Day

URL releasing protocol

Publication of results

Unpublished

URL related to results and publications

Number of participants that the trial has enrolled

Results

Results date posted

Results Delayed

Results Delay Reason

Date of the first journal publication of results

Baseline Characteristics

Participant flow

Adverse events

Outcome measures

Plan to share IPD

IPD sharing Plan description

Recruitment status

Open public recruiting

Date of protocol fixation

2016

Year

12

Month

01

Day

Date of IRB

Anticipated trial start date

2017

Year

02

Month

01

Day

Last follow-up date

Date of closure to data entry

Date trial data considered complete

Date analysis concluded

Other related information

Registered date

2016

Year

09

Month

26

Day

Last modified on

2017

Year

10

Month

05

Day

Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027823